Fig. 4: Combination treatment of RSL3 and COJEC chemotherapy.
From: Targeted ferroptosis induction enhances chemotherapy efficacy in chemoresistant neuroblastoma
A 3D representation of synergy analysis for a dose matrix of RSL3 and COJEC combinations in LU-NB-1 organoids. Bliss analysis performed with SynergyFinder. Negative scores (green) indicate antagonism, positive scores (red) indicate synergy, scores between −5 and 5 are considered additive. Average overall score -10.089. CL = COJEC Low dose; CH = COJEC High dose. B 3D representations of synergy analysis for dose matrices of RSL3 combined with the individual COJEC drugs (Cisplatin, Vincristine, Etoposide, Carboplatin, Cyclophosphamide). Bliss analysis performed with SynergyFinder. Negative scores (green) indicate antagonism, positive scores (red) indicate synergy. C RNA expression of GPX4, AIFM2 (FSP1), and HSPB1 in LU-NB PDX3-derived organoids (primary and relapsed), treated or not with high COJEC. One-way ANOVA statistical analysis followed by multiple comparison with Welch’s correction. D Viability of LU-NB-1 organoids transfected with GPX4 siRNAs or mock, and treated with DMSO (control), RSL3 2.5 μM, COJEC or the combination. LD low dose, HD high dose. E 3D representation of synergy analysis for a dose matrix combination of RSL3 and COJEC in LU-NB-1 organoids that had been transfected with GPX4 siRNA#1. Bliss analysis performed with SynergyFinder. Negative scores (green) indicate antagonism, positive scores (red) indicate synergy. F 3D representation of synergy analysis for a dose matrix combination of RSL3 and COJEC without etoposide in LU-NB-1. Bliss analysis performed with SynergyFinder. Negative scores (green) indicate antagonism, positive scores (red) indicate synergy.
